General Research
- HIV Non-Nuke Rilpivirine Less Likely Than Sustiva to Cause Vitamin D Drops (March 8, 2011)
From AIDSmeds.com
- When HIV Regimens Fail, Resistance Risk Appears Higher on NNRTIs Than Protease Inhibitors (October 3, 2008)
From aidsmap.com
- NNRTIs: The Next Generation Approaches (Part II) (December 14, 2006)
From TheBodyPRO.com
- NNRTIs: The Next Generation Approaches (Part I) (December 14, 2006)
From TheBodyPRO.com
- HIV JournalView: Adherence, Viral Fitness and NNRTI and PI Resistance (February/March 2006)
Bangsberg et al find that NNRTIs are more likely to suppress HIV than a single PI, but are also more vulnerable to resistance at low adherence levels.
From TheBodyPRO.com
- HIV JournalView: Dosing Adjustment Likely Needed for Statins Taken With NNRTIs (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from TheBodyPRO.com
- HIV JournalView: Low-Level Viremia May Slowly Breed Resistance, but Watch Out for NNRTIs (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from TheBodyPRO.com
- The Clinical Relevance of Non-Nucleoside Reverse Transcriptase Inhibitor Hypersusceptibility: A Prospective Cohort Analysis (July 11, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- In Routine Practice, the Durability of First-Line HAART Is Better for NNRTI Than PI-Based Regimens, Regardless of Baseline HIV Status (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- New Insights Into Mechanisms of HIV-1 Resistance to Reverse Transcriptase Inhibitors (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Distinguishable Lipid Profiles Between PI and NNRTI Therapy May Carry Different Risk of Cardiovascular Disease (CVD) (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Associations Between Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Use and HIV-Associated Lipodystrophy Syndrome (HALS) in the Dagna-LipART Cohort Study (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from TheBodyPRO.com
Efavirenz (Sustiva, Stocrin)
- Clinical Trials Using Efavirenz (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health
- Less-Used HIV Treatment for African Children More Effective (May 2, 2013)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Small Risk of Birth Defects Due to Efavirenz Confirmed in French Cohort (March 20, 2013)
From HIVandHepatitis.com
- Efavirenz Tied to Neurological Birth Defects (March 8, 2013)
From MedPage Today
- Small Risk of Neurological Birth Defects Due to Efavirenz Confirmed in French Cohort (March 6, 2013)
From aidsmap.com
- Long-Term Efavirenz Linked to Worse Neurocognitive Function in U.S. CHARTER Group (March 5, 2013)
From National AIDS Treatment Advocacy Project
- Sustiva, Atripla Tied to Neurologic Toxicity (November/December 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Popular HIV Drug May Cause Memory Declines (October 3, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Efavirenz Interaction Studies With TB Compounds Bedaquiline and Delamanid (September/October 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Study Summaries From ICAAC 2012 (September/October 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
VIEW ALL ARTICLES
Nevirapine (Viramune)
- Clinical Trials Using Nevirapine (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health
- Less-Used HIV Treatment for African Children More Effective (May 2, 2013)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Longer Use of Nevirapine Stops HIV in Babies (March 8, 2013)
From MedPage Today
- Nevirapine-Containing ART Does Not Reduce Combined Oral Contraceptive Effectiveness (January/February 2013)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Lipid Profile in Children in PREDICT: Immediate Versus Deferred Nevirapine-Based ART (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Adding Nevirapine to HIV Regimen Halves Newborn Transmission Rate (June 20, 2012)
Findings from NIH network support shift in prevention guidelines.
From U.S. National Institutes of Health
- Nevirapine Concentrations With Once- Versus Twice-Daily Dosing (September 24, 2011)
From National AIDS Treatment Advocacy Project
- Resistance Rates and Patterns Similar With Extended- and Immediate-Release Nevirapine (September 21, 2011)
From National AIDS Treatment Advocacy Project
- Optimising Infant HIV Treatment in Resource-Limited Settings: When Can Nevirapine Be Used? (March 7, 2011)
From aidsmap.com
- Six Months of Nevirapine Prophylaxis for Breastfeeding Infants Reduces Transmission by 76 Percent If Mother Not on ART (March 7, 2011)
From aidsmap.com
VIEW ALL ARTICLES
Email
